PMID- 28237613
OWN - NLM
STAT- MEDLINE
DCOM- 20180219
LR  - 20180219
IS  - 1578-8989 (Electronic)
IS  - 0025-7753 (Linking)
VI  - 148
IP  - 8
DP  - 2017 Apr 21
TI  - Effects of probiotics supplement in patients with type 2 diabetes mellitus: A 
      meta-analysis of randomized trials.
PG  - 362-370
LID - S0025-7753(16)30716-3 [pii]
LID - 10.1016/j.medcli.2016.11.036 [doi]
AB  - BACKGROUND AND OBJECTIVE: To objectively evaluate the effects of probiotics 
      supplement on glycemic control and lipid metabolism in patients with type 2 
      diabetes mellitus (T2DM). MATERIAL AND METHODS: The randomized controlled trials 
      (RCTs) with regard to the probiotics or synbiotics for the treatment of T2DM were 
      collected through retrieving 5 databases from their establishment to March 2016. 
      After study selection, quality assessment and data extraction were performed by 2 
      authors independently; and STATA software was used for statistical analysis. The 
      level of evidence was evaluated by applying the GRADE system. RESULTS: Twelve 
      RCTs involving 770 participants were enrolled. The results of the meta-analysis 
      showed that probiotics could significantly reduce fasting blood glucose by 
      -11.27mg/dL (95% CI -21.76 to -0.79; P<.001) and serum insulin concentration by 
      -2.36muU/mL (95% CI -4.01 to -0.72; P=.005), but with no significant reduction on 
      HbA(1c) (-0.19%; 95% CI -0.49 to 0.12; P=.23). Probiotics could significantly 
      reduce HOMA-IR of T2DM patients (-1.05; 95% CI -1.52 to -0.59; P<.001). 
      Nevertheless, the effect on QUICKI was negligible (0.00; 95% CI -0.00 to 0.01; 
      P=.27). Results also confirmed the significant lowering effect of probiotics on 
      total cholesterol (-8.49mg/dL; 95% CI -15.24 to -1.73; P=.014) and triglycerides 
      (TG; -23.66mg/dL; 95% CI -40.26 to -7.05; P<.001), as well as the elevating 
      effect on HDL-c (3.92mg/dL; 95% CI 2.14 to5.7; P<.01). However, there was no 
      significant change on LDL-c (-0.84mg/dL; 95% CI -5.84 to 4.17; P=.75). Subgroup 
      analysis was conducted for 2 outcomes, that is, serum insulin concentration and 
      TG, whose heterogeneity was too high. The results showed multiple species of 
      probiotics had stronger reduction effect on serum insulin concentration 
      (-3.32muU/mL; 95% CI -5.89 to-0.75; P=.001) and TG (-25.94mg/dL; 95% CI -65.33 to 
      13.44; P<.001). In addition, it also suggested that only the duration of 
      treatment for>/=8 weeks could significantly reduce TG by -24.47mg/dL (95% CI -40.15 
      to -8.78; P=.001). The duration of treatment for<8 weeks didn't result in 
      significant reduction on TG (-4.31mg/dL; 95% CI -37.69 to 29.06; P=.8). Finally, 
      all the evidences were at moderate and low levels according to the GRADE system. 
      CONCLUSION: As a kind of the potential biotherapeutics in the management of T2DM, 
      probiotics can improve glucose control and lipid metabolism.
CI  - Copyright (c) 2017 Elsevier Espana, S.L.U. All rights reserved.
FAU - Hu, Yi-Meng
AU  - Hu YM
AD  - Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      China.
FAU - Zhou, Feng
AU  - Zhou F
AD  - Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      China.
FAU - Yuan, Yin
AU  - Yuan Y
AD  - Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      China.
FAU - Xu, Yan-Cheng
AU  - Xu YC
AD  - Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 
      China. Electronic address: xycc567@126.com.
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
TT  - Efectos del suplemento de probioticos en pacientes con diabetes mellitus tipo 2: 
      metaanalisis de ensayos aleatorizados.
DEP - 20170222
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Triglycerides)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Biomarkers/blood
MH  - Blood Glucose/metabolism
MH  - Cholesterol/blood
MH  - Diabetes Mellitus, Type 2/blood/*therapy
MH  - Humans
MH  - Lipid Metabolism
MH  - Probiotics/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Triglycerides/blood
OTO - NOTNLM
OT  - Diabetes mellitus tipo 2
OT  - Meta-analysis
OT  - Metaanalisis
OT  - Probiotics
OT  - Probioticos
OT  - Type 2 diabetes mellitus
EDAT- 2017/02/27 06:00
MHDA- 2018/02/20 06:00
CRDT- 2017/02/27 06:00
PHST- 2016/07/01 00:00 [received]
PHST- 2016/10/31 00:00 [revised]
PHST- 2016/11/03 00:00 [accepted]
PHST- 2017/02/27 06:00 [pubmed]
PHST- 2018/02/20 06:00 [medline]
PHST- 2017/02/27 06:00 [entrez]
AID - S0025-7753(16)30716-3 [pii]
AID - 10.1016/j.medcli.2016.11.036 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2017 Apr 21;148(8):362-370. doi: 10.1016/j.medcli.2016.11.036. 
      Epub 2017 Feb 22.